Genmab Initiates Phase 2 Clinical Trial of Rina-S, an FRα-Targeted ADC, as Monotherapy for Non-Small Cell Lung Cancer Patients
Expansion of Key Pipeline Acquired Through ProfoundBio Acquisition
Genmab acquired ProfoundBio for $1.8 billion in May 2024, securing Rinatabart Sesutecan (Rina-S) along with a next-generation antibody-drug conjugate (ADC) platform. The initiation of the RAINFOL-05 (NCT07288177) Phase 2 clinical trial marks the first step in expanding the indications of Rina-S from its current use in gynecological cancers to non-small cell lung cancer (NSCLC). This demonstrates Genmab's commitment to Rina-S as a key growth driver following a major merger and acquisition (M&A) and subsequent pipeline prioritization. In a landscape where global pharmaceutical companies are diversifying their oncology portfolios, this trial represents a critical test for Genmab to demonstrate its unique anti-cancer activity.
Validation of Folate Receptor Alpha-Targeted Technology in Lung Cancer
Rina-S is an innovative drug candidate that selectively targets folate receptor alpha (FRα), which is overexpressed on cancer cells, and delivers a Topo1-inhibitor payload. While FRα-targeted therapies, such as AbbVie's Elahere, have primarily shown success in ovarian cancer, their efficacy in lung cancer remains an unexplored area. This Phase 2 trial will evaluate the efficacy of Rina-S as a monotherapy, precisely verifying its independent therapeutic potential. If the trial demonstrates significant response rates, it could provide a completely new alternative for NSCLC patients who exhibit strong resistance to existing standard treatments.
Strategic Intent and Patient Enrollment in the Phase 2 Trial Design
This Phase 2 trial is an open-label study that will enroll approximately 240 NSCLC patients worldwide, without a control group. Participants will receive the drug every three weeks, and tumor size changes and safety data, including adverse events, will be tracked for approximately 12 months. The single-arm design, without a control group, is a strategic choice to rapidly demonstrate the direct tumor-inhibiting effect of the new drug candidate and obtain early efficacy signals. This will enable Genmab to quickly make decisions regarding the initiation of next-generation combination therapy trials or late-stage clinical trials based on rapid clinical results.
Competitive Landscape and Opportunities in the Global NSCLC Market
The global NSCLC market is projected to grow rapidly from approximately $24.1 billion in 2026 to over $43.8 billion in 2030, making it a major battleground for oncology drugs. Currently, various drugs, including AstraZeneca and Daiichi Sankyo's TROP2-targeted ADC, are competing for market share. In this context, Rina-S can differentiate itself by targeting FRα, potentially positioning it as a novel treatment option for patients who do not respond to existing therapies or as a new first-line treatment. The industry is closely watching to see if the technology, which has already been validated in gynecological cancers with FDA Fast Track and Breakthrough Therapy designations, will also be successful in the lung cancer market.
This Phase 2 trial of Rina-S, acquired by Genmab for $1.8 billion, is a key milestone in expanding the FRα-targeted therapy, proven in ovarian and endometrial cancers, to the $24 billion NSCLC market. A key point of interest is whether the FRα-targeting mechanism, already demonstrated in ovarian cancer with AbbVie's Elahere, can achieve meaningful objective response rates (ORR) and progression-free survival (mPFS) in lung cancer patients. By offering a differentiated target compared to existing TROP2 ADC competitors such as AstraZeneca's Dato-DXd, it can be evaluated for its potential as a unique second-line treatment option for patients with resistance. Given that Rina-S has already secured FDA Fast Track and Breakthrough Therapy designations in ovarian cancer in 2024, successful results in the Phase 2 trial in lung cancer could significantly accelerate its commercialization timeline, leading to increased long-term pipeline value and potential for additional licensing deals.
Source: ClinicalTrials.gov (api_ct)